GlassScriptPhysician profile
Lori A Morrow
NPI 1023433232
$5,108.51
in general payments reported to CMS, 2019-2025
37 companies · $808 in 2025
The $808 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,246 · 2022: $972 · 2023: $1,114 · 2024: $968 · 2025: $808.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,817 · Education: $72.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,817.09 |
| Education | $72.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,124.22 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2, Octrode |
| Novo Nordisk INC | $823.87 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $378.20 | 2021-2024 | |
| Pfizer INC. | $325.55 | 2021-2025 | |
| Lilly USA, LLC | $241.39 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Astellas Pharma US INC | $231.54 | 2022-2025 | Veozah |
| Takeda Pharmaceuticals U.S.A., INC. | $210.60 | 2021-2025 | Trintellix |
| Amgen INC. | $207.50 | 2022-2025 | Repatha, Otezla, Evenity |
| Esperion Therapeutics, INC. | $194.46 | 2021-2025 | Nexletol |
| Amarin Pharma, INC. | $131.43 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $103.85 | 2021-2023 | Livalo |
| Neurocrine Biosciences, INC. | $90.30 | 2022-2024 | Ingrezza, Ongentys |
| Novartis Pharmaceuticals Corporation | $86.79 | 2021-2023 | |
| Glaxosmithkline, LLC. | $86.59 | 2021-2024 | Arexvy, Shingrix, Bexsero |
| Bayer Healthcare Pharmaceuticals INC. | $84.35 | 2021-2022 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $68.71 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Dexcom, INC. | $57.58 | 2023-2025 | Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals LP | $57.44 | 2024-2025 | Farxiga, Breztri, Airsupra |
| Edwards Lifesciences Corporation | $55.30 | 2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.47 | 2022-2023 | Jardiance |
| Biohaven Pharmaceuticals, INC. | $47.18 | 2021 | |
| Axsome Therapeutics, INC. | $45.00 | 2024 | Auvelity |
| Dynavax Technologies Corporation | $43.21 | 2023-2025 | Heplisav-B |
| Merck Sharp & Dohme LLC | $40.50 | 2021-2024 | Gardasil 9, Vaxneuvance, Gardasil |
| Biohaven Pharmaceutical Holding Company LTD. | $40.50 | 2022 | |
| Organon LLC | $37.46 | 2025 | Nexplanon |
| Phathom Pharmaceuticals, INC. | $36.90 | 2024-2025 | Voquezna |
| Medicure Pharma INC. | $31.30 | 2022 | |
| Medtronic, INC. | $27.31 | 2024 | Corevalve Evolut R |
| Stryker Corporation | $25.12 | 2025 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Eisai INC. | $24.46 | 2024 | |
| Xeris Pharmaceuticals, INC. | $21.38 | 2023 | Gvoke Hypopen |
| Sanofi-Aventis U.S. LLC | $18.95 | 2022 | |
| Evofem Biosciences, INC. | $16.61 | 2022 | |
| Bausch Health US, LLC | $15.71 | 2022 | |
| Shield Therapeutics INC | $14.47 | 2025 | |
| Pharmacosmos Therapeutics INC. | $12.31 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lori Morrow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.